ArticleJournal of Alzheimer's disease : JAD2013
Biomarkers of Alzheimer's disease among Mexican Americans.
Article in Journal of Alzheimer's disease : JAD, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 78 citations in OpenAlex.
- Circulating mitochondrial DNA: New indices of type 2 diabetes-related cognitive impairment in Mexican Americans.PloS one · 2019Trial
- A Precision Medicine Model for Targeted NSAID Therapy in Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2018Trial
- Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Elevated endogenous glucagon-like peptide-1 as a novel Alzheimer's disease biomarker associated with neuroinflammation and Aβ pathology.General psychiatry · 2026Article
- Mayo Test Drive Español: A model of digital cognitive test adaptation.The Clinical neuropsychologist · 2026Article
- Metabolic dysfunction associates with neuroimaging measures of brain structure and connectivity.Frontiers in neuroscience · 2026Article
- Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.medRxiv : the preprint server for health sciences · 2025Article
- Cerebrospinal fluid biomarkers of inflammation and immune activation associated with neurocognitive impairment among US Latinos with HIV.AIDS (London, England) · 2025Article
- Circulating adipokines and MRI markers of brain aging in middle-aged adults from the community.Journal of Alzheimer's disease : JAD · 2024Article
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Microbial determinants of dementia risk in subjects of Mexican descent with type 2 diabetes living in South Texas.medRxiv : the preprint server for health sciences · 2024Article
- Gut pathobiont enrichment observed in a population predisposed to dementia, type 2 diabetics of Mexican descent living in South Texas.Frontiers in microbiomes · 2024Article
- Article
- Integrative blood-based characterization of oxidative mitochondrial DNA damage variants implicates Mexican American's metabolic risk for developing Alzheimer's disease.Scientific reports · 2023Article
- Neuropsychiatric features in a multi-ethnic population with Alzheimer disease and mild cognitive impairment.International journal of geriatric psychiatry · 2023Article
- Integrative Blood-Based Characterization of Oxidative Mitochondrial DNA Damage Variants Implicates Mexican Americans' Metabolic Risk for Developing Alzheimer's Disease.Research square · 2023Article
- Comorbidities Incorporated to Improve Prediction for Prevalent Mild Cognitive Impairment and Alzheimer's Disease in the HABS-HD Study.Journal of Alzheimer's disease : JAD · 2023Article
- Hypermethylation at CREBBP Is Associated with Cognitive Impairment in a Mexican American Cohort.Journal of Alzheimer's disease : JAD · 2023Article
- Combination of Serum and Plasma Biomarkers Could Improve Prediction Performance for Alzheimer's Disease.Genes · 2022Article
- Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundMexican Americans are the fastest aging segment of the U.S. population, yet little scientific literature exists regarding the Alzheimer's disease (AD) among this segment of the population. The extant literature suggests that biomarkers of AD will vary according to race/ethnicity though no prior work has explicitly studied this possibility. The aim of this study was to create a serum-based biomarker profile of AD among Mexican American.
methodsData were analyzed from 363 Mexican American participants (49 AD and 314 normal controls) enrolled in the Texas Alzheimer's Research & Care Consortium (TARCC). Non-fasting serum samples were analyzed using a luminex-based multi-plex platform. A biomarker profile was generated using random forest analyses.
resultsThe biomarker profile of AD among Mexican Americans was different from prior work from non-Hispanic populations with regards to the variable importance plots. In fact, many of the top markers were related to metabolic factors (e.g., FABP, GLP-1, CD40, pancreatic polypeptide, insulin-like-growth factor, and insulin). The biomarker profile was a significant classifier of AD status yielding an area under the receiver operating characteristic curve, sensitivity, and specificity of 0.77, 0.92, and 0.64, respectively. Combining biomarkers with clinical variables yielded a better balance of sensitivity and specificity.
conclusionThe biomarker profile for AD among Mexican American cases is significantly different from that previously identified among non-Hispanic cases from many large-scale studies. This is the first study to explicitly examine and provide support for blood-based biomarkers of AD among Mexican Americans. Areas for future research are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.